Skip to main content

Jade Biosciences, Inc.

JBIO
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001798749

No open-market purchases or sales by Jade Biosciences, Inc. insiders were filed in the last 90 days; 153 institutions reported holding it in 13F filings for Q2 2026, worth $1.62B in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Jade Biosciences, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Jade Biosciences, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Jade Biosciences, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Eisner MarkDirector–Jun 26, 20261
Harwin Peter EvanDirector, 10% Owner1,897,677IndirectJun 11, 20262
Fairmount Healthcare Fund II L.P.Director, 10% Owner1,897,677IndirectJun 11, 20262
Fairmount Funds Management LLCDirector, 10% Owner1,897,677IndirectJun 11, 20262
Kiselak TomasDirector, 10% Owner1,897,677IndirectJun 11, 20262
Fairmount Healthcare Co-Invest IV L.P.Director, 10% Owner1,897,677IndirectJun 11, 20262
Dobmeier EricDirector–Jun 11, 20261
Lavelle ErinDirector–Jun 11, 20261
Klein Lawrence OttoDirector–Jun 11, 20261
Cain Christopher W.Director–Jun 11, 20261
Dahms Bradford D.Chief Financial Officer37,813Feb 13, 20261
King Andrew JamesSee Remarks386,113Feb 13, 20261
Frohlich TomChief Executive Officer86,331Feb 13, 20261
Bekiroglu ElizabethSee Remarks28,125Feb 13, 20261
RA Capital Healthcare Fund LP10% Owner1,287,858IndirectApr 30, 20250
Ra Capital Management, L.P.10% Owner1,287,858IndirectApr 30, 20250
Kolchinsky Peter10% Owner1,287,858IndirectApr 30, 20250
Shah Rajeev M.10% Owner1,287,858IndirectApr 30, 20250
Dake Benjamin TSEE REMARKS14,252Aug 2, 20240
RA Capital Nexus Fund, L.P.Director7,893,678IndirectJun 20, 20240
Eldridge George ASEE REMARKS5,022Jun 14, 20240
Gillies HunterCHIEF MEDICAL OFFICER5,602Jun 14, 20240
Verwijs MarinusCHIEF TECHNICAL OFFICER0Jun 14, 20240
Santel Donald JDirector–Jun 7, 20240
Iwicki Mark TDirector–Jun 7, 20240
Dorval AllisonDirector–Jun 7, 20240
Dable Habib JDirector–Jun 7, 20240
Resnick JoshuaDirector–Jun 7, 20240
Katabi MahaDirector, 10% Owner3,758,686IndirectJun 7, 20240
Grayzel David S.Director14,502IndirectJun 7, 20240
Noyes Timothy PCHIEF EXECUTIVE OFFICER0May 17, 20240
Niven RalphCHIEF SCIENTIFIC OFFICER1,609Feb 7, 20240
Pigot TimothyCHIEF COMMERCIAL OFFICER–Jan 24, 20240
Atlas Venture Fund XII, L.P.10% Owner2,327,909Jul 19, 20220
Cormorant Asset Management, LPOther: Former 10% Owner2,030,691IndirectJul 7, 20210
Chen BihuaOther: Former 10% Owner2,030,691IndirectJul 7, 20210
Cormorant Global Healthcare Master Fund, LPOther: Former 10% Owner2,030,691IndirectJul 7, 20210
Cormorant Private Healthcare Fund II, LPOther: Former 10% Owner2,030,691IndirectJul 7, 20210
Healy James10% Owner3,758,686Jul 6, 20210
Sofinnova Management X, L.P.10% Owner3,758,686Jul 6, 20210
Sofinnova Venture Partners X, L.P.10% Owner3,758,686Jul 6, 20210
Atlas Venture Associates XII, LLC10% Owner3,103,879Jul 6, 20210
Atlas Venture Associates XII, L.P.10% Owner3,103,879Jul 6, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jul 6, 2021 (view filing)Jul 24 daysGrayzel David S.DirectorPPurchase+535.7K$14.00+$7.50M+20.9%3.10M after
Jul 6, 2021 (view filing)Jul 24 daysKatabi MahaDirector, 10% OwnerPPurchase+357.1K$14.00+$5.00M+10.5%3.76M after
Jul 6, 2021 (view filing)4:26 PM ETJul 24 daysAtlas Venture Fund XII, L.P. and 2 others10% OwnerPPurchase+535.7K$14.00+$7.50M+20.9%3.10M afterDuplicate filing
Jul 6, 2021 (view filing)4:28 PM ETJul 24 daysHealy James and 2 others10% OwnerPPurchase+357.1K$14.00+$5.00M+10.5%3.76M afterDuplicate filing
Jul 6, 2021 (view filing)5:03 PM ETJul 24 daysRA Capital Healthcare Fund LP and 4 othersDirector, 10% OwnerPPurchase+2.79M$14.00+$39.0M+66.6%6.97M after
Jul 7, 2021 (view filing)4:45 PM ETJul 25 daysCormorant Asset Management, LP and 3 othersOther: Former 10% OwnerPPurchase+500.0K$14.00+$7.00M+32.7%2.03M after
Aug 10, 2022 (view filing)Aug 8-92 daysDake Benjamin TSee RemarksSSale−15.6K$24.31−$380.3K−100.0%0 after4 lots
Aug 12, 2022 (view filing)Aug 10-112 daysDake Benjamin TSee RemarksSSale−14.1K$24.07−$338.6K−100.0%0 after4 lots
Aug 18, 2022 (view filing)Aug 162 daysDake Benjamin TSee RemarksSSale−21.0K$23.00−$483.0K−100.0%0 after3 lots
Aug 19, 2022 (view filing)Aug 181 dayNiven RalphChief Scientific OfficerSSale−2.25K$21.18−$47.7K−58.3%1.61K after
Sep 7, 2022 (view filing)Sep 61 dayNiven RalphChief Scientific OfficerSSale−2.25K$19.00−$42.8K−58.3%1.61K after
Sep 8, 2022 (view filing)Sep 6-72 daysDake Benjamin TSee RemarksSSale−12.8K$18.50−$237.3K−100.0%0 after5 lots
Sep 12, 2022 (view filing)Sep 8-94 daysDake Benjamin TSee RemarksSSale−7.84K$17.80−$139.6K−100.0%0 after4 lots
Sep 14, 2022 (view filing)Sep 122 daysDake Benjamin TSEE REMARKSSSale−7.52K$17.33−$130.3K−100.0%0 after3 lots
Oct 7, 2022 (view filing)Oct 52 daysNiven RalphCHIEF SCIENTIFIC OFFICERSSale−2.25K$15.75−$35.4K−58.3%1.61K after2 lots
Oct 11, 2022 (view filing)Oct 6-75 daysDake Benjamin TSEE REMARKSSSale−23.6K$15.91−$374.7K−100.0%0 after5 lots
Oct 12, 2022 (view filing)Oct 102 daysDake Benjamin TSEE REMARKSSSale−4.95K$16.89−$83.7K−100.0%0 after2 lots
Oct 18, 2022 (view filing)Oct 14-174 daysDake Benjamin TSEE REMARKSSSale−4.29K$20.16−$86.6K−100.0%0 after2 lots
Oct 20, 2022 (view filing)Oct 182 daysDake Benjamin TSEE REMARKSSSale−5.71K$21.08−$120.3K−100.0%0 after
Nov 3, 2022 (view filing)Nov 21 dayVerwijs MarinusSENIOR VICE PRESIDENT, CMCSSale−1.13K$18.89−$21.3K−100.0%0 after
Nov 3, 2022 (view filing)Nov 12 daysNoyes Timothy PCHIEF EXECUTIVE OFFICERSSale−1.04K$19.50−$20.2K−100.0%0 after
Nov 9, 2022 (view filing)Nov 7-82 daysDake Benjamin TSEE REMARKSSSale−26.0K$18.25−$474.4K−100.0%0 after5 lots
Nov 9, 2022 (view filing)Nov 72 daysNiven RalphCHIEF SCIENTIFIC OFFICERSSale−2.25K$19.19−$43.2K−58.3%1.61K after4 lots
Nov 14, 2022 (view filing)Nov 9-115 daysDake Benjamin TSEE REMARKSSSale−22.0K$18.87−$415.2K−100.0%0 after5 lots
Nov 22, 2022 (view filing)Nov 18-224 daysEldridge George ASEE REMARKSSSale−1.04K$19.43−$20.1K−34.6%1.96K after4 lots
Nov 28, 2022 (view filing)Nov 235 daysEldridge George ASEE REMARKSSSale−1.26K$19.07−$24.0K−39.1%1.96K after
Dec 2, 2022 (view filing)Nov 302 daysEldridge George ASEE REMARKSSSale−85$19.06−$1.62K−4.2%1.96K after
Dec 2, 2022 (view filing)Dec 11 dayNoyes Timothy PCHIEF EXECUTIVE OFFICERSSale−15.0K$18.00−$270.0K−100.0%0 after
Dec 7, 2022 (view filing)Dec 52 daysNiven RalphCHIEF SCIENTIFIC OFFICERSSale−2.25K$17.38−$39.1K−58.3%1.61K after
Dec 8, 2022 (view filing)Dec 62 daysDake Benjamin TSEE REMARKSSSale−40.0K$17.67−$706.8K−100.0%0 after4 lots
Dec 9, 2022 (view filing)Dec 7-82 daysEldridge George ASEE REMARKSSSale−23.6K$21.85−$516.8K−92.3%1.96K after5 lots
Dec 12, 2022 (view filing)Dec 8-94 daysDake Benjamin TSEE REMARKSSSale−10.4K$22.73−$236.3K−100.0%0 after5 lots
Dec 13, 2022 (view filing)Dec 9-124 daysEldridge George ASEE REMARKSSSale−14.0K$28.43−$397.2K−87.7%1.96K after3 lots
Dec 14, 2022 (view filing)Dec 122 daysDake Benjamin TSEE REMARKSSSale−2.06K$29.43−$60.6K−100.0%0 after3 lots
Jan 5, 2023 (view filing)Jan 32 daysNoyes Timothy PCHIEF EXECUTIVE OFFICERSSale−15.0K$27.07−$406.1K−100.0%0 after4 lots
Jan 9, 2023 (view filing)Jan 54 daysNiven RalphCHIEF SCIENTIFIC OFFICERSSale−2.25K$26.40−$59.4K−58.3%1.61K after
Jan 9, 2023 (view filing)Jan 63 daysDake Benjamin TSEE REMARKSSSale−10.3K$25.98−$267.2K−100.0%0 after2 lots
Feb 3, 2023 (view filing)Feb 12 daysNoyes Timothy PCHIEF EXECUTIVE OFFICERSSale−15.0K$22.68−$340.2K−100.0%0 after2 lots
Feb 8, 2023 (view filing)Feb 62 daysNiven RalphCHIEF SCIENTIFIC OFFICERSSale−2.25K$24.27−$54.6K−58.3%1.61K after
Feb 8, 2023 (view filing)Feb 62 daysDake Benjamin TSEE REMARKSSSale−10.3K$24.59−$252.9K−100.0%0 after2 lots
Mar 3, 2023 (view filing)Mar 12 daysNoyes Timothy PCHIEF EXECUTIVE OFFICERSSale−15.0K$23.81−$357.2K−100.0%0 after4 lots
Mar 8, 2023 (view filing)Mar 62 daysNiven RalphCHIEF SCIENTIFIC OFFICERSSale−2.25K$23.75−$53.4K−58.3%1.61K after2 lots
Mar 8, 2023 (view filing)Mar 62 daysDake Benjamin TSEE REMARKSSSale−10.3K$23.73−$244.0K−100.0%0 after2 lots
Apr 5, 2023 (view filing)Apr 32 daysNoyes Timothy PCHIEF EXECUTIVE OFFICERSSale−15.0K$19.40−$291.0K−100.0%0 after2 lots
Apr 7, 2023 (view filing)Apr 52 daysNiven RalphCHIEF SCIENTIFIC OFFICERSSale−2.25K$18.20−$40.9K−58.3%1.61K after2 lots
Apr 7, 2023 (view filing)Apr 61 dayDake Benjamin TSEE REMARKSSSale−10.3K$18.17−$186.8K−100.0%0 after
Apr 25, 2023 (view filing)Apr 214 daysGillies HunterCHIEF MEDICAL OFFICERSSale−4.00K$19.50−$78.0K−67.1%1.96K after
May 3, 2023 (view filing)May 1-22 daysNoyes Timothy PCHIEF EXECUTIVE OFFICERSSale−15.7K$20.63−$323.8K−100.0%0 after2 lots10b5-1
May 5, 2023 (view filing)May 32 daysVerwijs MarinusSENIOR VICE PRESIDENT, CMCSSale−759$20.79−$15.8K−100.0%0 after
May 9, 2023 (view filing)May 54 daysNiven RalphCHIEF SCIENTIFIC OFFICERSSale−2.25K$20.87−$46.9K−58.3%1.61K after2 lots10b5-1